Regression estimates and incidence rate ratios from GLMER for number of papers (top) and coauthors (bottom). by William C. Barley (8915282)

Subjects:

Table 1_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Table 2_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Table 3_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Comparison of questionnaire scores among genotypes for the significant associations. by Dai Nogimura (21445649)

Subjects:

The pooled effect of all-cause mortality rate in non-health care workers and health care workers. by Zhuoyang Xia (21354186)

Subjects:

The pooled effect of COVID-19 infection rate in non-health care workers and health care workers. by Zhuoyang Xia (21354186)

Subjects:

Presentation 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated... by Xiaokang Wang (733379)

“…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”

Table 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated signall... by Xiaokang Wang (733379)

“…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”

Post-effect of GO and GO-GA NPs on progeny production of <i>Callosobruchus maculatus.</i> by Huda H. Elbehery (22492996)

Subjects:

Meta Analysis for Effectiveness of RFX for Primary and Secondary Prevention. by Yangyang Hu (3309009)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”

Study selection criteria. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects: “…demonstrate sustained effects…”